D359-0396 is an orally active NLRP3 inflammasome inhibitor; it inhibits macrophage pyroptosis and IL-1β release, suppresses oligomerization of NLRP3 and ASC, and inhibits cleavage of GSDMD; it ameliorates experimental autoimmune encephalomyelitis (EAE) in mice and improves survival in murine models of septic shock.